References
- Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335–71
- Melani AS, Pirrelli M, Sestini P, et al. GENEBU Project. Equipment and drugs used for home nebulizer therapy in Italy. Monaldi Arch Chest Dis 2002;57:231–6
- Rosenfeld M, Emerson J, Astley S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132:125–31
- McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother 2004;38:967–72
- McVicar W, Bonasia P, Ong S. Compatibility of levalbuterol inhalation solution mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium (Abstract). J Allergy Clin Immunol 2007;119:S1
- Kamin W, Schwabe A, Kramer I. Inhalation solutions: which ones are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006;5:205–13
- Berlinski A, Waldrep JC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med 2006;19:484–90